Genmab A/S (GMAB) News Today $20.59 -0.09 (-0.42%) As of 09:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GMAB Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As OneJune 23 at 10:03 AM | seekingalpha.comTransactions in Connection with Share Buy-back ProgramJune 23 at 8:19 AM | globenewswire.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Acquired by QRG Capital Management Inc.QRG Capital Management Inc. increased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 213.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,847 shares of the company's stock after purchasing an additJune 20, 2025 | marketbeat.comGAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)GAMMA Investing LLC lifted its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 1,465.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,482 shares of the company's stock after buying an additionaJune 19, 2025 | marketbeat.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseJune 17, 2025 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsJune 17, 2025 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 16, 2025 | globenewswire.comPark Avenue Securities LLC Takes Position in Genmab A/S (NASDAQ:GMAB)Park Avenue Securities LLC acquired a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 14,108 shares of the company's stock, valued at apJune 16, 2025 | marketbeat.comGenmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)June 15, 2025 | businesswire.comGenmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)June 15, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Wall Street ZenWall Street Zen lowered Genmab A/S from a "buy" rating to a "hold" rating in a report on Saturday.June 14, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by AnalystsGenmab A/S (NASDAQ:GMAB - Get Free Report) has been given an average rating of "Moderate Buy" by the thirteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold reJune 13, 2025 | marketbeat.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJune 12, 2025 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 10, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Downgraded to Hold Rating by Wall Street ZenWall Street Zen cut Genmab A/S from a "buy" rating to a "hold" rating in a research report on Friday.June 7, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Should You Sell?Genmab A/S (NASDAQ:GMAB) Shares Gap Down - What's Next?June 3, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up - What's Next?Genmab A/S (NASDAQ:GMAB) Shares Gap Up - Here's What HappenedJune 3, 2025 | marketbeat.comGenmab advances with lower dose of Rina-S in endometrial cancer trialsJune 3, 2025 | investing.comWhy Genmab Stock Smashed It on MondayJune 2, 2025 | finance.yahoo.comGenmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOLâ„¢-01 TrialJune 2, 2025 | businesswire.comGenmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 TrialJune 2, 2025 | globenewswire.comTransactions in Connection with Share Buy-back ProgramJune 2, 2025 | globenewswire.comLegacy Wealth Asset Management LLC Purchases 13,246 Shares of Genmab A/S (NASDAQ:GMAB)Legacy Wealth Asset Management LLC increased its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 36.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 49,367 shares of the company's stock after acquiring an additionJune 2, 2025 | marketbeat.com33,010 Shares in Genmab A/S (NASDAQ:GMAB) Bought by Mackenzie Financial CorpMackenzie Financial Corp bought a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 33,010 shares of the company's stock, valueJune 2, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Acquired by Squarepoint Ops LLCSquarepoint Ops LLC lifted its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 1,235.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 117,507 shares of the company's stock after purchasing an addMay 29, 2025 | marketbeat.comEmployees Retirement System of Texas Invests $1.65 Million in Genmab A/S (NASDAQ:GMAB)Employees Retirement System of Texas acquired a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 78,950 shares of the company's stock, valued at approximateMay 28, 2025 | marketbeat.comGenmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare ConferenceMay 27, 2025 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 26, 2025 | globenewswire.comGTS Securities LLC Acquires Shares of 74,356 Genmab A/S (NASDAQ:GMAB)GTS Securities LLC acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 74,356 shares of the company's stock, valued at approximately $1,552,000. A number of otMay 26, 2025 | marketbeat.comBank of America Corp DE Has $9.91 Million Position in Genmab A/S (NASDAQ:GMAB)Bank of America Corp DE lowered its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 55.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 474,858 shares of the company's stock after selling 579,588May 26, 2025 | marketbeat.comVoloridge Investment Management LLC Buys 561,767 Shares of Genmab A/S (NASDAQ:GMAB)Voloridge Investment Management LLC grew its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 102.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,110,191 shares of the company's stock after purchasing an additional 561May 25, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 88,146 Genmab A/S (NASDAQ:GMAB)Point72 Asset Management L.P. acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 88,146 shares of the company's stock, valued at approximately $1,840,000. A numbeMay 24, 2025 | marketbeat.comQuantinno Capital Management LP Buys 66,128 Shares of Genmab A/S (NASDAQ:GMAB)Quantinno Capital Management LP increased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 273.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 90,335 shares of the company's stock after purchasing an additional 66,May 24, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up - Should You Buy?Genmab A/S (NASDAQ:GMAB) Shares Gap Up - Should You Buy?May 23, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Bought by Two Sigma Advisers LPTwo Sigma Advisers LP grew its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 168.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,653,500 shares of the company's stock after purchasingMay 23, 2025 | marketbeat.comTwo Sigma Investments LP Raises Stake in Genmab A/S (NASDAQ:GMAB)Two Sigma Investments LP raised its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 122.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,706,364 shares of the company's stock after acquiring anMay 23, 2025 | marketbeat.comGenmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2025 | globenewswire.comGenmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2025 | businesswire.comOMERS ADMINISTRATION Corp Invests $378,000 in Genmab A/S (NASDAQ:GMAB)OMERS ADMINISTRATION Corp purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,100 shares of the company's stock, valued at approximately $378,000May 22, 2025 | marketbeat.comGenmab reports capital increase due to warrant exercisesMay 22, 2025 | uk.investing.comGenmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care ConferenceMay 21, 2025 | globenewswire.comGenmab AS ADR GMABMay 20, 2025 | morningstar.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 20, 2025 | globenewswire.comTema Etfs LLC Acquires New Position in Genmab A/S (NASDAQ:GMAB)Tema Etfs LLC acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 58,935 shares of the company's stock, valued at approximately $1,230,000. AMay 20, 2025 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from AnalystsGenmab A/S (NASDAQ:GMAB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating aMay 20, 2025 | marketbeat.comTransactions in Connection with Share Buy-back ProgramMay 19, 2025 | globenewswire.comBNP Paribas Financial Markets Invests $2.55 Million in Genmab A/S (NASDAQ:GMAB)BNP Paribas Financial Markets bought a new position in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 122,373 shares of the company's stock, valued at approximately $2,554,000. A number of otMay 19, 2025 | marketbeat.comNorthern Trust Corp Increases Stock Position in Genmab A/S (NASDAQ:GMAB)Northern Trust Corp boosted its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 18.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 599,381 shares of the company's stock after buying anMay 19, 2025 | marketbeat.comPoint72 Hong Kong Ltd Takes Position in Genmab A/S (NASDAQ:GMAB)Point72 Hong Kong Ltd purchased a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 43,671 shares of the company's stock, valued at approximately $911,000. A number oMay 18, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 24,894 Shares of Genmab A/S (NASDAQ:GMAB)Dimensional Fund Advisors LP lessened its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 35.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 45,615 shares of the company's stock after selling 24,894 shares during the period. DimensiMay 18, 2025 | marketbeat.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.880.62▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼66▲GMAB Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today Beigene News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Dr. Reddy's Laboratories News Today Ascendis Pharma A/S News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 6/24/2025 by MarketBeat.com Staff From Our Partners12 “perfect” stocksJoin the Dream Team and see how we can guarantee stock market wins Credentials are a good thing, especiall...Zacks | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs Tesla a buy right now?Wall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWall Street is using Bitcoin against youBitcoin is rising again, and institutions are pouring billions into Bitcoin ETFs. At first glance, that mig...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GMAB Stock Free GMAB Stock Alerts